Iron and immunity: A double-edged sword

European Journal of Clinical Investigation

Volumn 32, Issue SUPPL. 1, 2002, Pages 70-78

  Weiss, Günter ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cancer; Infection; Iron; Macrophages; Nitric oxide; Th 1 Th 2 cells

Indexed keywords

ANTIBODY; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; IRON; LACTOFERRIN; NITRIC OXIDE; TRANSFERRIN RECEPTOR; CYTOKINE;

ANEMIA; CELL PROLIFERATION; DISEASE COURSE; EFFECTOR CELL; GROWTH DISORDER; HEMOCHROMATOSIS; IMMUNITY; IMMUNOREGULATION; IMMUNOSURVEILLANCE; IRON BALANCE; IRON DEFICIENCY; IRON METABOLISM; IRON OVERLOAD; LYMPHOCYTE; MONOCYTE; PRIORITY JOURNAL; RETICULOENDOTHELIAL SYSTEM; REVIEW; TH1 CELL; TH2 CELL; THALASSEMIA; TISSUE INJURY; HUMAN; IMMUNE SYSTEM; IMMUNOLOGY; INFECTION; NEOPLASM; PHYSIOLOGY;

CYTOKINES; HUMANS; IMMUNE SYSTEM; INFECTION; IRON; NEOPLASMS;

EID: 19044389821     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1046/j.1365-2362.2002.0320s1070.x     Document Type: Review

References (109)

1. Brock JH, Halliday JW, Pippard MJ, Powell LW, eds. Iron Metabolism in Health and Disease. Philadelphia, PA: Saunders Company; 1994, pp. 353-91.
2. Seligman PA, Kovar J, Gelfand EW. Lymphocyte proliferation is controlled both by iron availability and regulation of iron uptake pathways. Pathobiology 1992;60:19-26.
3. De Sousa M. Immune cell functions in iron overload. Clin Exp Immunol 1989;75:1-6.
4. Laskey J, Webb I, Schulman HM, Ponka P. Evidence that transferrin supports cell proliferation by supplying iron for DNA synthesis. Exp Cell Res 1988;176:87-93.
5. Weiss G, Wachter H, Fuchs D. Linkage of cellular immunity to iron metabolism. Immunol Today 1995;16:495-500.
6. De Sousa M, Reimao R, Porto G, Grady RW, Hilgartner MW, Giardina P. Iron and lymphocytes: reciprocal regulatory interactions. Curr Stud Hematol Blood Transf 1992;58:171-7.
7. Brock JH. Iron in infection, immunity, inflammation and neoplasia. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, editors. Iron Metabolism in Health and Disease. Philadelphia, PA: Saunders Company; 1994: pp. 353-91.
8. Brekelmans P, van Soest P, Leenen PJ, van Ewijk W. Inhibition of proliferation and differentiation during early T cell development by anti-transferrin receptor antibody. Eur J Immunol 1994;24:2896-902.
9. Mainou-Fowler T, Brock JH. Effect of iron deficiency on the response of mouse lymphocytes to concanavalin A. Importance of transferrin bound iron. Immunology 1985;54:325-32.
10. Mosmann TR, Coffman RL. Th1 and Th2 cells: different patterns of lymphokine secretion leads to different functional properties. Annu Rev Immunol 1989;7:145-62.
11. Romagnani S. The Th1/Th2 paradigm. Immunol Today 1997;18:263-7.
12. Thorson JA, Smith KM, Gomez F, Naumann PW, Kemp JD. Role of iron in T cell activation: Th-1 clones differ from Th-2 clones in their sensitivity to inhibition for DNA synthesis caused by IGG MAbs against transferrin receptor and the iron chelator desferrioxamine. Cell Immimol 1991;134:126-7.
13. + lymphocytes and iron overload. Eur J Haematol 1994;52:283-8.
14. Moura E, Noordermeer MA, Verhoeven N, Verheul AFM, Marx JJM. Iron release from human monocytes after erythrophagocytosis in vitro: an investigation in normal subjects and hereditary hemochromatosis patients. Blood 1998;92:2511-9.
15. Weiss G. Iron acquisition by the reticuloendothelial system. In: Templeton D, editor. Molecular and Cellular Iron Transport. New York, NY: Marcel Dekker; 2002, pp. 467-86.
16. Rosen GM, Pou S, Ramos CL, Cohen MS, Britigan BE. Free radicals and phagocytic cells. FASEB J 1995;9:200-5.
17. Rouault TA, Klausner R. Regulation of iron metabolism in eukaryotes. Current Top Cell Regul 1997;35:1-6.
18. Hentze MW, Kühn LC. Molecular control of vertebrate iron metabolism: mRNA based regulatory circuits operated by iron, nitric oxide and oxidative stress. Proc Natl Acad Sci USA 1996;93:8175-80.
19. Muckenthaler M, Gray NK, Hentze MW. IRP-1 binding to ferritin mRNA prevents the recruitment of the small ribosomal subunit by the cap-binding complex eIF4F. Mol Cell 1998;2:383-8.
20. Casey JL, Koeller DM, Ramin VC, Klausner RD, Harford JB. Iron regulation of transferrin receptor mRNA levels requires iron-responsive elements and a rapid turnover determinant in the 3′ untranslated region of the mRNA. EMBO J 1989;8:3693-9.
21. Müllner EW, Neupert B, Kühn LC. A specific mRNA binding factor regulates the iron-dependent stability of cytoplasmatic transferrin receptor mRNA. Cell 1989;58:373-82.
22. Torti SV, Kwak EL, Miller SC, Miller LL, Ringold GM, Myambo KB, et al. The molecular cloning and characterization of ferritin heavy chain, a tumor necrosis factor inducible gene. J Biol Chem 1988;263:12638-44.
23. Wei YS, Miller SC, Tsuji Y, Torti S, Torti FM. Interleukin 1 induces ferritin heavy chain in human muscle cells. Biochem Biophys Res Commun 1989;169:298-6.
24. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996;1275:161-203.
25. Konijn AM, Carmel N, Levy R, Hershko C. Ferritin synthesis in inflammation. Mechanism of increased ferritin synthesis. Br J Haematol 1981;49:361-8.
26. Rogers JT. Ferritin translation by Interleukin-1 and interleukin-6:The role of sequences upstream of the start codons of the heavy and light subunit genes. Blood 1996;87:2525-37.
27. Tsuji Y, Miller LL, Miller SC, Torit SV, Torti FM. Tumor necrosis factor-α and interleukin 1-α regulate transferrin receptor in human diploid fibroblasts. J Biol Chem 1991;266:7257-61.
28. Alvarez-Hernandez X, Licega J, McKay I, Brock JH. Induction of hypoferremia and modulation of macrophage iron metabolism by tumor necrosis factor. Lab Invest 1989;61:319-22.
29. Donovan A, Brownlie A, Zhou Y, Shepard J, Pratt SJ, Moynihan J, et al. Positional cloning of zebrafish ferroportinl identifies a conserved vertebrate iron exporter. Nature 2000;403:776-81.
30. McKie AT, Marciani P, Rolfs A, Brennan K, Wehr K, Barrow D, et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol Cell 2000;5:299-309.
31. Abboud S, Haile DJ. A novel mammalian iron-regulated protein involved in intracellular iron metabolism. J Biol Chem 2000;275:19906-12.
32. Weiss G, Goossen B, Doppler W, Fuchs D, Pantopoulos K, Werner-Felmayer G, et al. Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway. EMBO J 1993;12:3651-7.
33. Drapier JC, Hirling H, Wietzerbin H, Kaldy P, Kühn LC. Biosynthesis of nitric oxide activates iron regulatory factor in macrophages. EMBO J 1993;12:3643-50.
34. Pantopoulos K, Hentze MW. Rapid responses to oxidative stress mediated by iron regulatory protein. EMBO J 1995;14:2917-24.
35. Cairo G, Castrusini E, Minotti G, Bernelli-Zazzera A. Superoxide and hydrogen peroxide-dependent inhibition of iron regulatory protein activity: a protective stratagem against oxidative injury. FASEB J 1996;10:1326-35.
36. Bourgeade MF, Silbermann F, Kühn L, Testa U, Peschle C, Memet S, et al. Post-transcriptional regulation of transferrin receptor mRNA by IFN-γ. Nucl Acids Res 1992;20:2997-3003.
37. Byrd T, Horwitz MA. Regulation of transferrin receptor expression and ferritin content in human mononuclear macrophages. Coordinate upregulation by iron transferrin and down-regulation by interferon gamma. J Clin Invest 1993;91:969-76.
38. Weiss G, Bogdan C, Hentze MW. Pathways for the regulation of macrophage iron metabolism by the anti-inflammatory cytokines IL-4 and IL-13. J Immunol 1997;158:420-5.
39. Mulero V, Brock JH. Regulation of iron metabolism in murine J774 macrophages: role of nitric oxide dependent and independent pathways following activation with gamma interferon and lipopolysaccharide. Blood 1999;94:2383-9.
40. Seiser C, Teixera S, Kühn LC. Interleukin-2 dependent transcriptional and posttranscriptional regulation of transfemn receptor mRNA. J Biol Chem 1993;268:13074-80.
41. Konijn A, Hershko C. The anaemia of inflammation and chronic disease. In: DeSousa M, Brock JH, editors. Iron in Immunity, Cancer and Inflammation. Chichester: Wiley and Sons; 1989, pp. 111-43.
42. Means RT, Krantz SB. Progress in understanding the pathogenesis of the anemia of chronic disease. Blood 1992;80:1639-47.
43. Weiss G. Iron and the anemia of chronic disease. Kidney Intern 1999;55 (Suppl. 69):12-7.
44. Weinberg ED. Modulation of intramacrophage iron metabolism during microbial cell invasion. Microbes Infect 2000;2:85-9.
45. Weiss G, Fuchs D, Hausen A, Reibnegger G, Werner ER, Werner-Felmayer G, et al. Iron modulates interferon-γ effects in the human myelomonocytic cell line THP-1. Exp Hematol 1992;20:605-10.
46. Recalcati S, Pometta R, Levi S, Conte D, Cairo G. Response of monocyte iron regulatory protein activity to inflammation: abnormal behavior in genetic hemochromatosis. Blood 1998;91:2565-72.
47. Weiss G, Werner-Felmayer G, Werner ER, Grünewald K, Wachter H, Hentze MW. Iron regulates nitric oxide synthase activity by controlling nuclear transcription. J Exp Med 1994;180:969-76.
48. MacMicking J, Xie QW, Nathan C. Nitric oxide and macrophage function. Annu Rev Immunol 1997;15:323-50.
49. Bogdan C. Nitric oxide and the regulation of gene expression. Trends Cell Biol 2001;11:66-75.
50. Mellilo G, Taylor LS, Brooks A, Musso T, Cox GW, Varesio L. Functional requirement of the hypoxia responsive element in the activation of the inducible nitric oxide synthase promoter by the iron chelator desferrioxamine. J Biol Chem 1997;272:12236-42.
51. Dlaska M, Weiss G. Central role of transcription factor NF-IL6 for cytokine and iron-mediated regulation of murine inducible nitric oxide synthase expression. J Immunol 1999;162:6171-7.
52. Gordeuk V, Thuma P, Brittenham G, McLaren C, Parry D, Backenstose A, et al. Effect of iron chelation therapy on recovery from deep coma in children with cerebral malaria. N Engl J Med 1992;327:1473-7.
53. Weiss G, Thuma PE, Mabeza F, Werner ER, Herold M, Gordeuk VR. Modulatory potential of iron chelation therapy on nitric oxide formation in cerebral malaria. J Infect Dis 1997;175:226.
54. Mabeza GF, Loyevsky M, Gordeuk VR, Weiss G. Iron chelation therapy for malaria: a review. Pharmacol Ther 1999;81:53-75.
55. Loyevsky M, Lytton SD, Mester B, Libman J, Shanzer A, Cabantchik ZI. The antimalarial action of desferal involves a direct access route to erythrocytic (Plasmodium falciparum) parasites. J Clin Invest 1993;91:218-24.
56. Hershko C, Gordeuk VR, Thuma PE, Theanacho EN, Spira DT, Hider RC, et al. The antimalarial effect of iron chelators: studies in animal models and in humans with mild falciparum malaria. J Inorg Biochem 1992;47:267-77.
57. Fritsche G, Larcher C, Schennach H, Weiss G. Regulatory Interactions between Iron and Nitric Oxide Metabolism for Immune Defense against Plasmodium falciparum Infection. J Infect Dis 2001;183:1388-94.
58. Eide DJ. Metal ion transport in eukaryotic microorganisms: insights from Saccharomyces cerevisiae. Adv Microb Physiol 2000;43:1-38.
59. Genco CA, White Dixon D. Emerging strategies in microbial haem capture. Mol Microbiol 2001;39:1-11.
60. Shedlofsky SI. Role of iron in the natural history and clinical course of hepatitis C disease. Hepatogastroenterology 1998;45:349-55.
61. Weiss G, Umlauft F, Urbanek M, Herold M, Lovevsky M, Offner F, et al. Associations between cellular immune effector function, iron metabolism, and disease activity in patients with chronic hepatitis C virus infection. J Infect Dis 1999;180:1542-8.
62. Pietrangelo A. Iron, oxidative stress and liver fibrogenesis. J Hepatol 1998;28 (Suppl. 1):8-13.
63. Sartori M, Andorno S, Rigamonti C, Boldorini R. Chronic hepatitis C treated with phlebotomy alone: biochemical and histological outcome. Dig Liver Dis 2001;33:157-62.
64. Di Bisceglie AM, Bonkovsky HL, Chopra S, Flamm S, Reddy RK, Grace N, et al. Iron reduction as an adjuvant to interferon therapy in patients with chronic hepatitis C who have previously not responded to interferon: a multicenter, prospective, randomized, controlled trial. Hepatology 2000;32:135-8.
65. Gordeuk VR, McLaren CE, MacPhail AP, Deichsel G, Bothwell TH. Associations of iron overload in Africa with hepatocellular carcinoma and tuberculosis: Strachan's 1929 Thesis revisited. Blood 1996;87:3470-6.
66. Gomes MS, Boelaert JR, Appelberg R. Role of iron in experimental Mycobacterium avium infection. J Clin Virol 2001;20:117-22.
67. Olakanmi O, Britigan BE, Schlesinger LS. Gallium disrupts iron metabolism of mycobacteria residing within human macrophages. Infect Immun 2000;68:5619-27.
68. Gordeuk VR, Delanghe JR, Langlois MR, Boelaert JR. Iron status and the outcome of HIV infection: an overview. J Clin Virol 2001;20:111-5.
69. Weinberg ED. Iron loading and disease surveillance. Emerg Infect Dis 1999;5:346.
70. Stevens RG, Graubard BI, Micozzi MS, Neriishi K, Blumberg BS. Moderate elevation of body iron level and increased risk of cancer occurrence and death. Int J Cancer 1994;56:364-9.
71. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988;319: 1047-52.
72. Gangaidzo IT, Gordeuk VR. Hepatocellular carcinoma and African iron overload. Gut 1995;37:727-30.
73. Moura E, Verheul AF, Marx JJM. A functional defect in hereditary haemochromatosis monocytes and monocyte-derived macrophages. Eur J Clin Invest 1998;28:164-73.
74. Niederau C, Fischer R, Sonnenberg A, Stremmel W, Trampisch HJ, Strohmeyer G. Survival and causes of death in cirrhotic and in noncirrhotic patients with primary hemochromatosis. N Engl J Med 1985;313:1256-62.
75. Fracanzani AL, Conte D, Fraquelli M, Taioli E, Mattioli M, Losco A, et al. Increased cancer risk in a cohort of 230 patients with hereditary hemochromatosis in comparison to matched control patients with non-iron-related chronic liver disease. Hepatology 2001;33:647-51.
76. Weinberg ED. The role of iron in cancer. Eur J Cancer Prev 1996;5:19-36.
77. van Asbeck BS, Georgiou NA, van der Bruggen T, Oudshoorn M, Nottet HS, Marx JJM. Anti-HIV effect of iron chelators: different mechanisms involved. J Clin Virol 2001;20:141-7.
78. Bergeron RJ, Wiegand J, Brittenham GM. HBED: the continuing development of a potential alternative to deferoxamine for iron-chelating therapy. Blood 1999;93:370-5.
79. Tilbrook GS, Hider RC. Iron chelators for clinical use. Met Ions Biol Syst 1998;35:691-730.
80. Vidal SM, Malo D, Vogan K, Skamene E, Gros P. Natural resistance to infections with intracellular parasites: Isolation of a candidate for Beg. Cell 1993;73:469-76.
81. Bellamy R. The natural resistance-associated macrophage protein and susceptibility to intracellular pathogens. Microbes Infect 1999;1:23-7.
82. Canonne-Hergaux F, Gruenheid S, Govoni G, Gros P. The Nramp1 protein and its role in resistance to infection and macrophage function. Proc Assoc Am Physicians 1999;111:283-9.
83. Baker ST, Barton CH, Biggs TE. A negative autoregulatory link between Nramp1 function and expression. J Leukoc Biol 2000;67:501-7.
84. Zoller H, Oexle H, Koch R, Kishi F, Andrews N, Weiss G. Iron regulates the expression of a host resistance gene (NRAMP-1) in macrophages. 9th International Congress on Infectious Diseases, Buenos Aires, April 9-13; 2000, p. 132 (Abstract).
85. Atkinson PG, Barton CH. High level expression of NRAMP1G169 in RAW264-7 cell transfectants: analysis of intracellular iron transport. Immunology 1999;96:656-62.
86. Asp169. J Leukoc Biol 1999;66:113-9.
87. +/bivalent cation antiporter. Biochem J 2001;354:511-9.
88. Hackam DJ, Rotstein O, Zhang D, Gruenheid S, Gros P, Grinstein S. Host resistance to intracellular infection: mutation of natural resistance associated macrophage protein 1 impairs phagosomal acidification. J Exp Med 1998;188:351-64.
89. Jabado N, Jankowski A, Dougaparsad S, Picard V, Grinstein S, Gros P. Natural resistance to intracellular infections: natural resistance-associated macrophage protein 1 (Nramp1) functions as a pH-dependent manganese transporter at the phagosomal membrane. J Exp Med 2000;192:1237-48.
90. Vidal S, Belouchi AM, Cellier M, Beatty B, Gros P. Cloning and characterization of a second human NRAMP gene on chromosome 12q13. Mamm Genome 1995;6:224-30.
91. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, et al. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997;388:482-8.
92. Andrews NC, Levy JE. Iron is hot: Update on the pathophysiology of hemochromatosis. Blood 1998;92:1845-52.
93. Wardrop SL, Richardson DR. Interferon-gamma and lipopolysaccharide regulate the expression of Nramp2 and increase the uptake of iron from low relative molecular mass complexes by macrophages. Eur J Biochem 2000;267: 6586-93.
94. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruudy DA, Basava A, et al. A novel MHC class I like gene is mutated in patients with hereditary haemochromatosis. Nature Genet 1996;13:399-408.
95. Waheed AM, Parkkila S, Zhou XY, Tomatsu S, Tsuchihashi Z, Feder JN, et al. Hereditary hemochromatosis: Effects of C282V and H63D mutations on association with β2-microglobulin, intracellular processing, and cell surface expression of the HFE protein in COS-7 cells. Proc Natl Acad Sci USA 1997;94:12384-9.
96. Santos M, Schilham MW, Rademakers LHPM, Marx JJM, de Sousa M, Clevers H. Defective iron homeostasis in p2-microglobulin knockout mice recapitulates hereditary hemochromatosis in man. J Exp Med 1996;184:1975-85.
97. Rothenberg BE, Voland JR. β2 knockout mice develop parenchymal iron overload: a putative role for class I genes of the major histocompatibility complex in iron metabolism. Proc Natl Acad Sci USA 1996;93:1529-34.
98. + cells. Science 1990;248:1227-30.
99. Feder JN, Penny DM, Irrinki A, Lee VK, Lebron JA, Watson N, et al. The hemochromatosis gene product complexes with the transferrin receptor and lowers its affinity for ligand binding. Proc Natl Acad Sci USA 1998;95:1472-7.
100. Lebron JA, Bennett MJ, Vaughn DE, Chirino AJ, Snow PM, Mintier GA, et al. Crystal structure of the hemochromatosis protein HFE and characterization of its interaction with transferrin receptor. Cell 1998;93:111-23.
101. Pietrangelo A, Casalgrandi G, Quaglino D, Gualdi R, Conte D, Milani S, et al. Duodenal ferritin synthesis in genetic hemochromatosis. Gastroemerology 1995;108:208-17.
102. Fleming RE, Migas MC, Zhou X, Jiang J, Britton RS, Brunt EM, et al. Mechanism of increased iron absorption in murine model of hereditary hemochromatosis: increased duodenal expression of the iron transporter DMT-1. Proc Natl Acad Sci USA 1999;96:3143-8.
103. Zoller H, Pietrangelo A, Vogel W, Weiss G. Duodenal metal-transporter (DMT-1) expression in patients with hereditary hemochromatosis. Lancet 1999;353:2120-3.
104. Powell LW, Subramaniam VN, Yapp TR. Haemochromatosis in the new millennium. J Hepatol 2000;32:48-62.
105. TenElshof AE, Brittenham G, Chorney KA, Page MJ, Gerhard G, Cable EE, et al. γδ intraepithelial lymphocytes drive tumor necrosis factor-α responsiveness to intestinal iron challenge: relevance to hemochromatosis. Immunol Rev 1999;167:223-32.
106. Brock JH. Lactoferrin. A multifunctional immunoregulatory protein? Immunol Today 1995;16:417-9.
107. Mincheva-Nilsson L, Hammarstrom S, Hammarstrom ML. Activated human gamma delta T-lymphocytes express functional lactoferrin receptors. Scand J Immunol 1997;46:609-18.
108. Crouch SPM, Slater KJ, Fletcher J. Regulation of cytokine release from mononuclear cells by iron binding protein lactoferrin. Blood 1992;80:235-40.
109. Shau H, Kim A, Golub SH. Modulation of natural killer and lymphokine activated killer cell cytotoxiciy by lactoferrin. J Leukoc Biol 1992;51:343-9.